Advanced liver damage is common in people with undiagnosed hepatitis C in US survey

Keith Alcorn
Published: 25 April 2015

Around one in five people with hepatitis C in the United States who do not know of their infection may already have advanced liver damage and be in urgent need of treatment, according to a cross-sectional survey of participants in the National Health and Nutritional Examination Survey (NHANES) presented by Prowpanga Udompap at the International Liver Congress in Vienna, Austria, on Saturday.

The United States Centers for Disease Control and Prevention (CDC) recommends that everyone born between 1945 and 1965 – the 'baby boom' generation – should have a test for hepatitis C virus (HCV) at least once, due to the high prevalence of hepatitis C in this age group.

However, primary care physicians have been slow to implement the guidance, and many people who might have been at risk of acquiring hepatitis C during military service, as a result of blood transfusion or through injecting drugs are unaware of the availability of hepatitis C testing and new curative treatment.

As people infected with hepatitis C age, their risk of progressive liver damage grows, but without diagnosis many people infected in the 1960s and 1970s will be unaware that they have suffered liver damage.

Without treatment, people with advanced fibrosis may progress to advanced stages of liver cirrhosis, suffer liver failure and serious extra-hepatic symptoms or develop liver cancer.

Treatment guidelines recommend that people with advanced fibrosis (stages F3 and F4) should receive immediate treatment owing to the high risk of liver disease progression.

In order to quantify the scale of advanced fibrosis in people with undiagnosed hepatitis C, Prowpanga Udompap and colleagues of Stanford University used data from the National Health and Nutrition Examination Survey (NHANES II), a cohort of 62,000 American adults. In this cohort 45,000 people have been tested for HCV antibodies, of which 591 were positive and 420 had chronic HCV infection confirmed by RNA testing. Of these, 417 had AST and ALT liver enzyme measurements and 163 of these had responded to questions about HCV awareness, and this subset was used to quantify the prevalence of cirrhosis among undiagnosed people. Forty-nine per cent were unaware of their HCV infection.

The researchers used the FIB-4 system to calculate the risk of advanced fibrosis. FIB-4 is a validated algorithm for calculating the stage of liver damage using ALT, AST, platelet levels and age. It has a high positive predictive value for diagnosing F3/F4 fibrosis.

This study used FIB-4 cut-offs of <1.45 for low probability of fibrosis, 1.45-<3.25 for intermediate fibrosis, and >3.25 for advanced fibrosis (F3 and F4).

Of the respondents with known HCV infection, the proportion with a high, intermediate and low probability of advanced fibrosis was 14.5%, 40.3%, 45.2%, respectively; in those with undiagnosed HCV the results were 19.1%, 30.9%, 50.0%, respectively.

Using the aspartate aminotransferase/platelet ratio index (APRI) produced a similar result, although the estimate of advanced fibrosis in undiagnosed people was lower (11%).

A recent study by the US CDC, which used FIB-4 to calculate liver fibrosis stage in people with a positive HCV RNA test between 2010 and 2013, found that 40% of all patients, and 46% of those in the 1945-1965 birth cohort, had advanced fibrosis (F3 or F4).

Reference

Udompap P et al. Advanced fibrosis is common in individuals whose hepatitis C has not been diagnosed: Results from the National Health and Nutrition Examination Survey 2001-2012. J Hepatology 62 (50th International Liver Congress), abstract 0120, 2015.

Hepatitis information

For more information on hepatitis visit infohep.org.

Infohep is a project we're working on with the World Hepatitis Alliance and the European Liver Patients Association.

Visit infohep.org >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.